Equities research analysts at Barclays PLC began coverage on shares of REGENXBIO Inc. (NASDAQ:RGNX) in a research report issued to clients and investors on Wednesday. The firm set an “overweight” rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on RGNX. Raymond James Financial, Inc. began coverage on shares of REGENXBIO in a research note on Thursday, October 12th. They set an “outperform” rating and a $39.00 target price on the stock. Bank of America Corporation restated a “buy” rating and set a $38.00 target price (up from $33.00) on shares of REGENXBIO in a research note on Monday, October 9th. Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a research note on Wednesday, October 18th. ValuEngine lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Finally, Morgan Stanley restated an “overweight” rating and set a $34.00 target price on shares of REGENXBIO in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $43.17.

Shares of REGENXBIO (NASDAQ:RGNX) opened at $29.10 on Wednesday. REGENXBIO has a one year low of $16.30 and a one year high of $36.10.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.04. REGENXBIO had a negative net margin of 764.06% and a negative return on equity of 39.33%. The firm had revenue of $1.34 million for the quarter. equities analysts predict that REGENXBIO will post -2.71 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “REGENXBIO Inc. (RGNX) Receives New Coverage from Analysts at Barclays PLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/regenxbio-inc-rgnx-receives-new-coverage-from-analysts-at-barclays-plc/1719300.html.

In related news, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $27.71, for a total value of $277,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $24.95, for a total value of $499,000.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $499,000. The disclosure for this sale can be found here. Insiders sold 210,500 shares of company stock valued at $5,957,300 over the last ninety days. 17.00% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pura Vida Investments LLC boosted its holdings in REGENXBIO by 17.7% in the third quarter. Pura Vida Investments LLC now owns 33,920 shares of the biotechnology company’s stock valued at $1,118,000 after purchasing an additional 5,100 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in REGENXBIO by 5.1% in the third quarter. Perceptive Advisors LLC now owns 1,441,186 shares of the biotechnology company’s stock valued at $47,487,000 after purchasing an additional 70,000 shares in the last quarter. Jane Street Group LLC acquired a new position in REGENXBIO in the third quarter valued at approximately $476,000. RTW Investments LP boosted its holdings in REGENXBIO by 20.9% in the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock valued at $50,710,000 after purchasing an additional 266,235 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in REGENXBIO by 25.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 122,509 shares of the biotechnology company’s stock valued at $4,037,000 after purchasing an additional 24,814 shares in the last quarter. 72.09% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.